Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: Report of twenty-one cases

Maria Anna Capozzo, Giulia Schillani, Eugenio Aguglia, Maurizio De Vanna, Luigi Grassi, Maria Anna Conte, Tullio Giraldi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The aim of this study was to examine the effects of the SSRI antidepressant drug citalopram on anxiety, depression and mental adjustment to cancer in terminally ill cancer patients, considering also the 5-HTTLPR genetic polymorphism. A group of twenty-one consecutive patients admitted to the hospice of the Casa di Cura Pineta del Carso (Trieste, Italy) with different types of advanced cancer, who were clinically judged to require treatment with an antidepressive drug, was treated with citalopram for two weeks. The response was determined and related to 5-HTTLPR. Citalopram significantly reduced the scores on the depression and anxiety subscales of the Hospital Anxiety and Depression Scale (HADS). When the effects of citalopram were analyzed in relation to the 5-HTTLPR polymorphism, the HADS depression score was significantly decreased only in patients with the "l/l" allelic variant of the serotonin transporter conferring high functional activity, while the score of the Mini-MAC fatalism scale was significantly increased in patients carrying at least one "s" allele. These preliminary findings seem to indicate that two weeks of treatment with citalopram are effective in reducing depressive symptoms in terminally ill cancer patients. Moreover, the effects of citalopram on fatalism as a strategy of mental adaptation to cancer, and on depressive symptoms depend on the allelic variants of the 5-HTTLPR genotype of the patients. These results seem to encourage the examination of a larger patient sample and of different treatment schedules, as well as a more thorough characterization of fatalism as a coping strategy in cancer patients.

Original languageEnglish
Pages (from-to)479-483
Number of pages5
JournalTumori
Volume95
Issue number4
Publication statusPublished - 2009

Fingerprint

Terminally Ill
Serotonin Plasma Membrane Transport Proteins
Citalopram
Depression
Neoplasms
Anxiety
Social Adjustment
Hospices
Genetic Polymorphisms
Italy
Antidepressive Agents
Appointments and Schedules
Therapeutics
Alleles
Genotype

Keywords

  • Antidepressant drugs
  • Mental adaptation to cancer
  • Palliative care
  • Pharmacogenetics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Capozzo, M. A., Schillani, G., Aguglia, E., De Vanna, M., Grassi, L., Conte, M. A., & Giraldi, T. (2009). Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: Report of twenty-one cases. Tumori, 95(4), 479-483.

Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients : Report of twenty-one cases. / Capozzo, Maria Anna; Schillani, Giulia; Aguglia, Eugenio; De Vanna, Maurizio; Grassi, Luigi; Conte, Maria Anna; Giraldi, Tullio.

In: Tumori, Vol. 95, No. 4, 2009, p. 479-483.

Research output: Contribution to journalArticle

Capozzo, MA, Schillani, G, Aguglia, E, De Vanna, M, Grassi, L, Conte, MA & Giraldi, T 2009, 'Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: Report of twenty-one cases', Tumori, vol. 95, no. 4, pp. 479-483.
Capozzo MA, Schillani G, Aguglia E, De Vanna M, Grassi L, Conte MA et al. Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: Report of twenty-one cases. Tumori. 2009;95(4):479-483.
Capozzo, Maria Anna ; Schillani, Giulia ; Aguglia, Eugenio ; De Vanna, Maurizio ; Grassi, Luigi ; Conte, Maria Anna ; Giraldi, Tullio. / Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients : Report of twenty-one cases. In: Tumori. 2009 ; Vol. 95, No. 4. pp. 479-483.
@article{c0cbf8f2484b4083b1b3611d428b3594,
title = "Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: Report of twenty-one cases",
abstract = "The aim of this study was to examine the effects of the SSRI antidepressant drug citalopram on anxiety, depression and mental adjustment to cancer in terminally ill cancer patients, considering also the 5-HTTLPR genetic polymorphism. A group of twenty-one consecutive patients admitted to the hospice of the Casa di Cura Pineta del Carso (Trieste, Italy) with different types of advanced cancer, who were clinically judged to require treatment with an antidepressive drug, was treated with citalopram for two weeks. The response was determined and related to 5-HTTLPR. Citalopram significantly reduced the scores on the depression and anxiety subscales of the Hospital Anxiety and Depression Scale (HADS). When the effects of citalopram were analyzed in relation to the 5-HTTLPR polymorphism, the HADS depression score was significantly decreased only in patients with the {"}l/l{"} allelic variant of the serotonin transporter conferring high functional activity, while the score of the Mini-MAC fatalism scale was significantly increased in patients carrying at least one {"}s{"} allele. These preliminary findings seem to indicate that two weeks of treatment with citalopram are effective in reducing depressive symptoms in terminally ill cancer patients. Moreover, the effects of citalopram on fatalism as a strategy of mental adaptation to cancer, and on depressive symptoms depend on the allelic variants of the 5-HTTLPR genotype of the patients. These results seem to encourage the examination of a larger patient sample and of different treatment schedules, as well as a more thorough characterization of fatalism as a coping strategy in cancer patients.",
keywords = "Antidepressant drugs, Mental adaptation to cancer, Palliative care, Pharmacogenetics",
author = "Capozzo, {Maria Anna} and Giulia Schillani and Eugenio Aguglia and {De Vanna}, Maurizio and Luigi Grassi and Conte, {Maria Anna} and Tullio Giraldi",
year = "2009",
language = "English",
volume = "95",
pages = "479--483",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients

T2 - Report of twenty-one cases

AU - Capozzo, Maria Anna

AU - Schillani, Giulia

AU - Aguglia, Eugenio

AU - De Vanna, Maurizio

AU - Grassi, Luigi

AU - Conte, Maria Anna

AU - Giraldi, Tullio

PY - 2009

Y1 - 2009

N2 - The aim of this study was to examine the effects of the SSRI antidepressant drug citalopram on anxiety, depression and mental adjustment to cancer in terminally ill cancer patients, considering also the 5-HTTLPR genetic polymorphism. A group of twenty-one consecutive patients admitted to the hospice of the Casa di Cura Pineta del Carso (Trieste, Italy) with different types of advanced cancer, who were clinically judged to require treatment with an antidepressive drug, was treated with citalopram for two weeks. The response was determined and related to 5-HTTLPR. Citalopram significantly reduced the scores on the depression and anxiety subscales of the Hospital Anxiety and Depression Scale (HADS). When the effects of citalopram were analyzed in relation to the 5-HTTLPR polymorphism, the HADS depression score was significantly decreased only in patients with the "l/l" allelic variant of the serotonin transporter conferring high functional activity, while the score of the Mini-MAC fatalism scale was significantly increased in patients carrying at least one "s" allele. These preliminary findings seem to indicate that two weeks of treatment with citalopram are effective in reducing depressive symptoms in terminally ill cancer patients. Moreover, the effects of citalopram on fatalism as a strategy of mental adaptation to cancer, and on depressive symptoms depend on the allelic variants of the 5-HTTLPR genotype of the patients. These results seem to encourage the examination of a larger patient sample and of different treatment schedules, as well as a more thorough characterization of fatalism as a coping strategy in cancer patients.

AB - The aim of this study was to examine the effects of the SSRI antidepressant drug citalopram on anxiety, depression and mental adjustment to cancer in terminally ill cancer patients, considering also the 5-HTTLPR genetic polymorphism. A group of twenty-one consecutive patients admitted to the hospice of the Casa di Cura Pineta del Carso (Trieste, Italy) with different types of advanced cancer, who were clinically judged to require treatment with an antidepressive drug, was treated with citalopram for two weeks. The response was determined and related to 5-HTTLPR. Citalopram significantly reduced the scores on the depression and anxiety subscales of the Hospital Anxiety and Depression Scale (HADS). When the effects of citalopram were analyzed in relation to the 5-HTTLPR polymorphism, the HADS depression score was significantly decreased only in patients with the "l/l" allelic variant of the serotonin transporter conferring high functional activity, while the score of the Mini-MAC fatalism scale was significantly increased in patients carrying at least one "s" allele. These preliminary findings seem to indicate that two weeks of treatment with citalopram are effective in reducing depressive symptoms in terminally ill cancer patients. Moreover, the effects of citalopram on fatalism as a strategy of mental adaptation to cancer, and on depressive symptoms depend on the allelic variants of the 5-HTTLPR genotype of the patients. These results seem to encourage the examination of a larger patient sample and of different treatment schedules, as well as a more thorough characterization of fatalism as a coping strategy in cancer patients.

KW - Antidepressant drugs

KW - Mental adaptation to cancer

KW - Palliative care

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=70350040935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350040935&partnerID=8YFLogxK

M3 - Article

C2 - 19856660

AN - SCOPUS:70350040935

VL - 95

SP - 479

EP - 483

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -